atogepant + onabotulinumtoxinA

**atogepant + onabotulinumtoxinA** is a combination therapy for the prevention of **chronic migraine**. Atogepant is an orally administered small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, reducing migraine by blocking CGRP-mediated nociception and neurogenic inflammation[6][5]. OnabotulinumtoxinA (brand name Botox) is a biologic neurotoxin injected locally; it blocks the release of neurotransmitters and neuropeptides by cleaving SNAP-25, a component of the SNARE complex, thereby inhibiting exocytosis in motor and sensory neurons and reducing pain transmission[2][8]. The combination offers potentially additive or synergistic benefit, targeting complementary populations of meningeal nociceptors—atogepant predominantly inhibits Aδ fibers and onabotulinumtoxinA unmyelinated C fibers—thus more effectively reducing activation and sensitization of trigeminovascular neurons implicated in migraine[3][4].

Other names

atogepant + onabotulinumtoxinAQulipta + Botox